Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival

Ilaria Pergolini, Vicente Morales-Oyarvide, Mari Mino-Kenudson, Kim C. Honselmann, Matthew W. Rosenbaum, Sabikun Nahar, Marina Kem, Cristina R. Ferrone, Keith D. Lillemoe, Nabeel Bardeesy, David P. Ryan, Sarah P Thayer, Andrew L. Warshaw, Carlos Fernández-Del Castillo, Andrew S. Liss

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Patient-derived xenograft (PDX) tumors are powerful tools to study cancer biology. However, the ability of PDX tumors to model the biological and histological diversity of pancreatic ductal adenocarcinoma (PDAC) is not well known. In this study, we subcutaneously implanted 133 primary and metastatic PDAC tumors into immunodeficient mice. Fifty-seven tumors were successfully engrafted and even after extensive passaging, the histology of poorly-, moderately-, and well-differentiated tumors was maintained in the PDX models. Moreover, the fibroblast and collagen contents in the stroma of patient tumors were recapitulated in the corresponding PDX models. Analysis of the clinicopathological features of patients revealed xenograft tumor engraftment was associated with lymphovascular invasion (P = 0.001) and worse recurrence-free (median, 7 vs. 16 months, log-rank P = 0.047) and overall survival (median, 13 vs. 21 months, log-rank P = 0.038). Among successful engraftments, median time of growth required for reimplantation into new mice was 151 days. Reflective of the inherent biological diversity between PDX tumors with rapid (<151 days) and slow growth, differences in their growth were maintained during extensive passaging. Rapid growth was additionally associated with lymph node metastasis (P = 0.022). The association of lymphovascular invasion and lymph node metastasis with PDX formation and rapid growth may reflect an underlying biological mechanism that allows these tumors to adapt and grow in a new environment. While the ability of PDX tumors to mimic the cellular and non-cellular features of the parental tumor stroma provides a valuable model to study the interaction of PDAC cells with the tumor microenvironment, the association of successful engraftment with adverse clinicopathological features suggests PDX models over represent more aggressive forms of this disease.

Original languageEnglish (US)
Article numbere0182855
JournalPloS one
Volume12
Issue number8
DOIs
StatePublished - Aug 2017

Fingerprint

adenocarcinoma
Heterografts
Tumors
Adenocarcinoma
neoplasms
Survival
Neoplasms
Growth
Biodiversity
metastasis
lymph nodes
Lymph Nodes
Neoplasm Metastasis
Histology
Tumor Microenvironment
Replantation
Fibroblasts
mice
histology
fibroblasts

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Pergolini, I., Morales-Oyarvide, V., Mino-Kenudson, M., Honselmann, K. C., Rosenbaum, M. W., Nahar, S., ... Liss, A. S. (2017). Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PloS one, 12(8), [e0182855]. https://doi.org/10.1371/journal.pone.0182855

Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. / Pergolini, Ilaria; Morales-Oyarvide, Vicente; Mino-Kenudson, Mari; Honselmann, Kim C.; Rosenbaum, Matthew W.; Nahar, Sabikun; Kem, Marina; Ferrone, Cristina R.; Lillemoe, Keith D.; Bardeesy, Nabeel; Ryan, David P.; Thayer, Sarah P; Warshaw, Andrew L.; Fernández-Del Castillo, Carlos; Liss, Andrew S.

In: PloS one, Vol. 12, No. 8, e0182855, 08.2017.

Research output: Contribution to journalArticle

Pergolini, I, Morales-Oyarvide, V, Mino-Kenudson, M, Honselmann, KC, Rosenbaum, MW, Nahar, S, Kem, M, Ferrone, CR, Lillemoe, KD, Bardeesy, N, Ryan, DP, Thayer, SP, Warshaw, AL, Fernández-Del Castillo, C & Liss, AS 2017, 'Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival', PloS one, vol. 12, no. 8, e0182855. https://doi.org/10.1371/journal.pone.0182855
Pergolini, Ilaria ; Morales-Oyarvide, Vicente ; Mino-Kenudson, Mari ; Honselmann, Kim C. ; Rosenbaum, Matthew W. ; Nahar, Sabikun ; Kem, Marina ; Ferrone, Cristina R. ; Lillemoe, Keith D. ; Bardeesy, Nabeel ; Ryan, David P. ; Thayer, Sarah P ; Warshaw, Andrew L. ; Fernández-Del Castillo, Carlos ; Liss, Andrew S. / Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. In: PloS one. 2017 ; Vol. 12, No. 8.
@article{9661bba8fd0f4e958756e0d27831b380,
title = "Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival",
abstract = "Patient-derived xenograft (PDX) tumors are powerful tools to study cancer biology. However, the ability of PDX tumors to model the biological and histological diversity of pancreatic ductal adenocarcinoma (PDAC) is not well known. In this study, we subcutaneously implanted 133 primary and metastatic PDAC tumors into immunodeficient mice. Fifty-seven tumors were successfully engrafted and even after extensive passaging, the histology of poorly-, moderately-, and well-differentiated tumors was maintained in the PDX models. Moreover, the fibroblast and collagen contents in the stroma of patient tumors were recapitulated in the corresponding PDX models. Analysis of the clinicopathological features of patients revealed xenograft tumor engraftment was associated with lymphovascular invasion (P = 0.001) and worse recurrence-free (median, 7 vs. 16 months, log-rank P = 0.047) and overall survival (median, 13 vs. 21 months, log-rank P = 0.038). Among successful engraftments, median time of growth required for reimplantation into new mice was 151 days. Reflective of the inherent biological diversity between PDX tumors with rapid (<151 days) and slow growth, differences in their growth were maintained during extensive passaging. Rapid growth was additionally associated with lymph node metastasis (P = 0.022). The association of lymphovascular invasion and lymph node metastasis with PDX formation and rapid growth may reflect an underlying biological mechanism that allows these tumors to adapt and grow in a new environment. While the ability of PDX tumors to mimic the cellular and non-cellular features of the parental tumor stroma provides a valuable model to study the interaction of PDAC cells with the tumor microenvironment, the association of successful engraftment with adverse clinicopathological features suggests PDX models over represent more aggressive forms of this disease.",
author = "Ilaria Pergolini and Vicente Morales-Oyarvide and Mari Mino-Kenudson and Honselmann, {Kim C.} and Rosenbaum, {Matthew W.} and Sabikun Nahar and Marina Kem and Ferrone, {Cristina R.} and Lillemoe, {Keith D.} and Nabeel Bardeesy and Ryan, {David P.} and Thayer, {Sarah P} and Warshaw, {Andrew L.} and {Fern{\'a}ndez-Del Castillo}, Carlos and Liss, {Andrew S.}",
year = "2017",
month = "8",
doi = "10.1371/journal.pone.0182855",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival

AU - Pergolini, Ilaria

AU - Morales-Oyarvide, Vicente

AU - Mino-Kenudson, Mari

AU - Honselmann, Kim C.

AU - Rosenbaum, Matthew W.

AU - Nahar, Sabikun

AU - Kem, Marina

AU - Ferrone, Cristina R.

AU - Lillemoe, Keith D.

AU - Bardeesy, Nabeel

AU - Ryan, David P.

AU - Thayer, Sarah P

AU - Warshaw, Andrew L.

AU - Fernández-Del Castillo, Carlos

AU - Liss, Andrew S.

PY - 2017/8

Y1 - 2017/8

N2 - Patient-derived xenograft (PDX) tumors are powerful tools to study cancer biology. However, the ability of PDX tumors to model the biological and histological diversity of pancreatic ductal adenocarcinoma (PDAC) is not well known. In this study, we subcutaneously implanted 133 primary and metastatic PDAC tumors into immunodeficient mice. Fifty-seven tumors were successfully engrafted and even after extensive passaging, the histology of poorly-, moderately-, and well-differentiated tumors was maintained in the PDX models. Moreover, the fibroblast and collagen contents in the stroma of patient tumors were recapitulated in the corresponding PDX models. Analysis of the clinicopathological features of patients revealed xenograft tumor engraftment was associated with lymphovascular invasion (P = 0.001) and worse recurrence-free (median, 7 vs. 16 months, log-rank P = 0.047) and overall survival (median, 13 vs. 21 months, log-rank P = 0.038). Among successful engraftments, median time of growth required for reimplantation into new mice was 151 days. Reflective of the inherent biological diversity between PDX tumors with rapid (<151 days) and slow growth, differences in their growth were maintained during extensive passaging. Rapid growth was additionally associated with lymph node metastasis (P = 0.022). The association of lymphovascular invasion and lymph node metastasis with PDX formation and rapid growth may reflect an underlying biological mechanism that allows these tumors to adapt and grow in a new environment. While the ability of PDX tumors to mimic the cellular and non-cellular features of the parental tumor stroma provides a valuable model to study the interaction of PDAC cells with the tumor microenvironment, the association of successful engraftment with adverse clinicopathological features suggests PDX models over represent more aggressive forms of this disease.

AB - Patient-derived xenograft (PDX) tumors are powerful tools to study cancer biology. However, the ability of PDX tumors to model the biological and histological diversity of pancreatic ductal adenocarcinoma (PDAC) is not well known. In this study, we subcutaneously implanted 133 primary and metastatic PDAC tumors into immunodeficient mice. Fifty-seven tumors were successfully engrafted and even after extensive passaging, the histology of poorly-, moderately-, and well-differentiated tumors was maintained in the PDX models. Moreover, the fibroblast and collagen contents in the stroma of patient tumors were recapitulated in the corresponding PDX models. Analysis of the clinicopathological features of patients revealed xenograft tumor engraftment was associated with lymphovascular invasion (P = 0.001) and worse recurrence-free (median, 7 vs. 16 months, log-rank P = 0.047) and overall survival (median, 13 vs. 21 months, log-rank P = 0.038). Among successful engraftments, median time of growth required for reimplantation into new mice was 151 days. Reflective of the inherent biological diversity between PDX tumors with rapid (<151 days) and slow growth, differences in their growth were maintained during extensive passaging. Rapid growth was additionally associated with lymph node metastasis (P = 0.022). The association of lymphovascular invasion and lymph node metastasis with PDX formation and rapid growth may reflect an underlying biological mechanism that allows these tumors to adapt and grow in a new environment. While the ability of PDX tumors to mimic the cellular and non-cellular features of the parental tumor stroma provides a valuable model to study the interaction of PDAC cells with the tumor microenvironment, the association of successful engraftment with adverse clinicopathological features suggests PDX models over represent more aggressive forms of this disease.

UR - http://www.scopus.com/inward/record.url?scp=85029131402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029131402&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0182855

DO - 10.1371/journal.pone.0182855

M3 - Article

C2 - 28854237

AN - SCOPUS:85029131402

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e0182855

ER -